Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sucampo Pharma Europe, a wholly-owned European subsidiary of Sucampo Pharmaceuticals has filed a marketing authorization application or MAA for Amitiza or lubiprostone, 24mcg, for the indication of chronic idiopathic constipation in adults in the UK.
Subscribe to our email newsletter
The application has been filed using the decentralized procedure with the Medicines and Healthcare Products Regulatory Agency of the UK serving as the reference member state with additional applications to be filed with the member states of Belgium, Denmark, France, Germany, Ireland, the Netherlands, Spain and Sweden. Other than the US and Canada, Sucampo Pharmaceuticals retains all commercial rights for Amitiza for Europe and the rest of the world.
Ryuji Ueno, chairman and CEO of Sucampo Pharmaceuticals, said: “Sucampo is expanding to Europe. Our filing in the UK represents a major event in our plans for international expansion. We see great opportunities because Amitiza is claimed to be the only approved US prescription drug for the treatment of chronic idiopathic constipation in adults. It also claimed that,in Europe, there are no approved drugs for this indication.”